This $350,000 Project Grant award from the National Center for Advancing Translational Sciences (NCATS), under the 93.350 CFDA program, supports the development of the Codomax EPI-MAX platform. This integrated omics and computational technology leverages cellular stress responses to enhance the production of difficult-to-express therapeutic proteins, with a focus on improving secretion and preventing aggregation in the Pichia pastoris expression system. The key products or services to be...
This $427,095 Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) supports the development of a novel microfluidic droplet-based platform (MDP) technology to generate and analyze a 3D biomimetic multicellular immunogenic tumor model. The goal is to establish multiple levels of hypoxia within the tumor-chip, investigate spatiotemporal interaction between the tumor microenvironment and cancer-immune cells during...
This Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program (CFDA 47.084) provides $275,000 to Dcan Biosciences LLC to develop an advanced microfluidic system for cancer diagnosis and monitoring. The system aims to isolate and assess circulating tumor cells (CTCs) and CTC clusters (CTCCs) from patient blood samples to enable highly sensitive and accurate liquid biopsies. Key objectives include designing a hybrid microfluidic device for...
The Terasaki Institute for Biomedical Innovation received a $611,129 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The funding will support the development and validation of a multi-organ-on-a-chip (MOC) platform to study the underlying mechanisms of antibody-mediated rejection (ABMR) in organ transplantation. The MOC platform will integrate a vascularized liver-on-a-chip (VLOC) and a...
This Project Grant award from the National Center for Advancing Translational Sciences (CFDA 93.350) provides $1,077,369 to Captis Diagnostics Inc. to develop and commercialize their proprietary Lipid Nanoprobe (LNP) system for rapid, efficient, and cost-effective isolation of extracellular vesicles (EVs) from non-invasive bodily fluids such as blood plasma, serum, urine, and saliva. The project aims to further optimize the LNP technology for EV enrichment and evaluate/validate the LNP prototype...
The federal Project Grant award R41GM154612, in the amount of $333,048.00, was provided by the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) to Imagen Bioworks Inc. in Houston, TX. The objective of this project is to develop a versatile 2-photon microscopy-based platform, dubbed "2P-SPOTLIGHT," to isolate individual cells from 3D tissue samples after spatial and temporal profiling. This innovative method will...
This federal Project Grant award from the National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), will fund the design and preparation of diagnostic biomarker reference standards for mucopolysaccharidosis type I (MPS-I) and type II (MPS-II). These lysosomal storage disorders are included in newborn screening programs, but current first-tier enzyme activity screening has a high rate of false...
This $500,000 Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program aims to develop a novel human stem cell-based microfluidic developmental toxicology platform. The University of Michigan will receive funding from September 2022 to August 2024 to conduct technological development of a repeatable, controllable, high-throughput microfluidic system for generating three-dimensional multicellular organoid models for toxicity testing. The platform seeks...
This Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), provides $447,304 to The Regents of the University of California, Berkeley (UC Berkeley) to develop a compact single-molecule assay (SIMOA) system. The objective is to create an integrated circuit chip that seamlessly combines microfluidics and electronics to enable sensitive...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training Program (CFDA 93.859) provides $298,999 to Numentus Technologies Inc. to develop a high-throughput, high-content imaging platform for the analysis of extracellular vesicles (EVs). The goal is to create a novel technology that can rapidly identify and characterize specific subpopulations of EVs, such as exosomes from human cancer cells and outer membrane...